Prm162 - A Piecewise Approach to the Extrapolation of Invasive Disease-Free Survival (Idfs) in the Adjuvant Treatment of Her2+ Breast Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2281
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Adjuvant Treatment of HER2-positive Breast Cancer: Winning Efforts Continue to Improve HER2-positive Patient Outcome Long-Term

Breast Cancer Research
Cancer ResearchOncology
2012English

A miRNA-based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab-Based Treatment

Scientific Reports
Multidisciplinary
2016English

Factors Affecting Distant Disease-Free Survival for Primary Invasive Breast Cancer: Use of a Log-Normal Survival Model

Annals of Surgical Oncology
OncologySurgery
2000English

The Analysis of Relapse-Free Survival Curves: Implications for Evaluating Intensive Systemic Adjuvant Treatment Regimens for Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Neratinib in Adjuvant Treatment of Patients With HER2-positive Breast Cancer — Less Is More?

Oncology in Clinical Practice
Oncology
2019English

Cyclin D3 Predicts Disease-Free Survival in Breast Cancer

Cancer Cell International
Cancer ResearchOncologyGenetics
2015English

New Developments in the Treatment of HER2-positive Breast Cancer

Breast Cancer: Targets and Therapy
Oncology
2012English

A Case-Control Study of the HER2 Ile655Val Polymorphism in Relation to Risk of Invasive Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2005English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy